These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 20548940)

  • 1. Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs.
    Berger EA; Pastan I
    PLoS Pathog; 2010 Jun; 6(6):e1000803. PubMed ID: 20548940
    [No Abstract]   [Full Text] [Related]  

  • 2. An anti-CD45RO immunotoxin kills HIV-latently infected cells from individuals on HAART with little effect on CD8 memory.
    Saavedra-Lozano J; Cao Y; Callison J; Sarode R; Sodora D; Edgar J; Hatfield J; Picker L; Peterson D; Ramilo O; Vitetta ES
    Proc Natl Acad Sci U S A; 2004 Feb; 101(8):2494-9. PubMed ID: 14983037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence of genital tract T cell responses in HIV-infected women on highly active antiretroviral therapy.
    Mkhize NN; Gumbi PP; Liebenberg LJ; Ren Y; Smith P; Denny L; Passmore JA
    J Virol; 2010 Oct; 84(20):10765-72. PubMed ID: 20686039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study.
    Kaufmann D; Pantaleo G; Sudre P; Telenti A
    Lancet; 1998 Mar; 351(9104):723-4. PubMed ID: 9504519
    [No Abstract]   [Full Text] [Related]  

  • 5. Low-level viremia and proviral DNA impede immune reconstitution in HIV-1-infected patients receiving highly active antiretroviral therapy.
    Ostrowski SR; Katzenstein TL; Thim PT; Pedersen BK; Gerstoft J; Ullum H
    J Infect Dis; 2005 Feb; 191(3):348-57. PubMed ID: 15633093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between cellular human immunodeficiency virus DNA level and immunological parameters in patients with undetectable plasma viremia level during highly active antiretroviral therapy.
    Sarmati L; Parisi SG; Nicastri E; d'Ettorre G; Palmisano L; Andreotti M; Andreoni C; Giuliano M; Gatti F; Boldrin C; Palù G; Vullo V; Vella S; Andreoni M
    J Clin Microbiol; 2005 Dec; 43(12):6183-5. PubMed ID: 16333125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seroreversion of HIV antibodies in patients with prolonged suppression of viraemia under HAART.
    Amor A; Toro C; Jiménez V; Simón A; Ramos B; Soriano V
    AIDS; 2006 Jun; 20(10):1460-2. PubMed ID: 16791025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MHC class II genotype and the control of viremia in HIV-1-infected individuals on highly active antiretroviral therapy.
    Blankson JN; Siliciano RF
    J Clin Invest; 2001 Mar; 107(5):549-51. PubMed ID: 11238554
    [No Abstract]   [Full Text] [Related]  

  • 9. Significant link between sCD30 changes and HIV viremia in patients treated with HAART.
    Biswas P; Cozzi-Lepri A; Delfanti F; Galli A; Colangeli V; Moioli MC; Scarchilli A; Abrescia N; Vigevani G; D'Arminio-Monforte A; Novati R; Lazzarin A
    J Med Virol; 2006 Dec; 78(12):1513-9. PubMed ID: 17063513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opportunistic infection as a cause of transient viremia in chronically infected HIV patients under treatment with HAART.
    Jones LE; Perelson AS
    Bull Math Biol; 2005 Nov; 67(6):1227-51. PubMed ID: 16023709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunologic dynamics in hemophiliac patients infected with hepatitis C virus and human immunodeficiency virus: influence of antiretroviral therapy.
    Yokozaki S; Takamatsu J; Nakano I; Katano Y; Toyoda H; Hayashi K; Hayakawa T; Fukuda Y
    Blood; 2000 Dec; 96(13):4293-9. PubMed ID: 11110704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of in vivo and ex vivo levels of TH1 and TH2 cytokines with viremia in HAART patients with and without opportunistic infections.
    Sindhu S; Toma E; Cordeiro P; Ahmad R; Morisset R; Menezes J
    J Med Virol; 2006 Apr; 78(4):431-9. PubMed ID: 16482539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term CD4+ T-cell response in HIV-1-infected patients continuing combination antiretroviral therapy despite high-level viremia and drug resistance.
    Dionisio D; Vivarelli A; Zazzi M; Esperti F; Fabbri C; Giorgi M; Menichini B
    Eur J Clin Microbiol Infect Dis; 2003 Jan; 22(1):69-71. PubMed ID: 12582750
    [No Abstract]   [Full Text] [Related]  

  • 14. Characteristics of HIV-1-specific CD8 T-cell responses and their role in loss of viremia in children chronically infected with HIV-1 undergoing highly active antiretroviral therapy.
    Zhang Z; Zhao QX; Fu JL; Yao JX; He Y; Jin L; Wang FS
    Chin Med J (Engl); 2006 Dec; 119(23):1949-57. PubMed ID: 17199938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 plasma viremia not increased in patients receiving highly active antiretroviral therapy after influenza vaccination.
    Macías J; Pineda JA; Leal M; Abad MA; Delgado J; Rosa R; Rubio A; Sánchez-Quijano A; Lissen E
    Eur J Clin Microbiol Infect Dis; 2001 Jan; 20(1):46-8. PubMed ID: 11245323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An anti-CD45RO immunotoxin kills latently infected human immunodeficiency virus (HIV) CD4 T cells in the blood of HIV-positive persons.
    Saavedra-Lozano J; McCoig C; Xu J; Cao Y; Keiser P; Ghetie V; Siliciano RF; Siliciano JD; Picker LJ; Ramilo O; Vitetta ES
    J Infect Dis; 2002 Feb; 185(3):306-14. PubMed ID: 11807712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV reservoir dynamics in the face of highly active antiretroviral therapy.
    Costiniuk CT; Jenabian MA
    AIDS Patient Care STDS; 2015 Feb; 29(2):55-68. PubMed ID: 25412339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy.
    Dinoso JB; Rabi SA; Blankson JN; Gama L; Mankowski JL; Siliciano RF; Zink MC; Clements JE
    J Virol; 2009 Sep; 83(18):9247-57. PubMed ID: 19570871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kaposi sarcoma herpes virus antibody response and viremia following highly active antiretroviral therapy in the Swiss HIV Cohort study.
    Sullivan SG; Hirsch HH; Franceschi S; Steffen I; Amari EB; Mueller NJ; Magouras I; Biggar RJ; Rickenbach M; Clifford GM;
    AIDS; 2010 Sep; 24(14):2245-52. PubMed ID: 20543658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.